CHMP

EMA's CHMP Recommends Restricting Third-Line Ovarian Cancer Indication for Clovis' Rubraca

Gilead's Tecartus Gets EMA CHMP Recommendation in Advanced ALL

Bristol Myers Squibb's Opdualag Gets EMA CHMP Recommendation for Biomarker-Selected Melanoma

EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications

EMA's CHMP Recommends Novartis' Scemblix for TKI-Intolerant Chronic Myeloid Leukemia Patients

European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC

Novartis Nabs European Approval for Kymriah in Follicular Lymphoma

EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers

EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors

EMA's CHMP Issues Positive Recommendations for Novartis' Kymriah, Janssen's Carvykti

CHMP Recommends Approval for Opdivo in PD-L1-Positive Esophageal, Urothelial Cancers

CHMP Issues Positive Opinion for Immunocore's Kimmtrak as Metastatic Uveal Melanoma Treatment

EMA's CHMP Issues Positive Opinion on BMS' Breyanzi for Lymphoma Patients

EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer

EMA's CHMP Issues Positive Opinion on Merck KGaA's Tepmetko for Lung Cancer Subgroup

EMA Accepts Marketing Application for Atara Biotherapeutics' Tabelecleucel

CHMP Recommends Amgen's Lumykras for KRAS G12C-Mutated NSCLC

CHMP Recommends Gilead's Trodelvy for Pretreated TNBC

CHMP Recommends BMS' Opdivo Plus Chemo for First-Line PD-L1-Positive Gastric Cancers